{"id":"W4206807902","doi":"10.1200/jco.2022.40.4_suppl.008","title":"Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oxaliplatin; Internal medicine; Bevacizumab; Oncology; Nivolumab; Colorectal cancer; Clinical endpoint; Cancer; Randomized controlled trial; Chemotherapy; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001173886,0.0006759195,0.001014739,0.0002409742,0.0002319306,0.0005589331,0.0005221596,0.000766841,0.004183964],"category_scores_gemma":[0.001124838,0.0003281288,0.0009840651,0.0002060554,0.0005260643,0.000462857,0.0003076947,0.0014321,0.0004413547],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001185441,"about_ca_system_score_gemma":0.001205748,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001289468,"about_ca_topic_score_gemma":0.004830771,"domain_scores_codex":[0.9996662,0.0001853438,0.0000233197,0.00004869243,0.00002829654,0.00004816453],"domain_scores_gemma":[0.9995172,0.0001155884,0.0001371003,0.00001911932,0.00002159234,0.0001893268],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9252779,0.01315062,0.00228106,0.0008644172,0.0008144164,0.00004698628,0.0000884144,0.0009321209,0.005842977,0.0001341652,0.001608581,0.04895818],"study_design_scores_gemma":[0.6938205,0.2902142,0.008850029,0.000123544,0.001070753,0.00009924188,0.00004736207,0.001079725,0.00227379,0.0001672464,0.002229051,0.00002449111],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923638,0.002277659,0.0002561358,0.0002700925,0.0001277505,0.002416848,0.0009203733,0.0000374813,0.001329951],"genre_scores_gemma":[0.9924631,0.00137537,0.0008802739,0.0004234153,0.0001121857,0.001850318,0.001002894,0.00001043435,0.001881987],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004183964,"threshold_uncertainty_score":0.01399678,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2352463132794324,"score_gpt":0.501040987722398,"score_spread":0.2657946744429657,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}